<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629717</url>
  </required_header>
  <id_info>
    <org_study_id>201801105</org_study_id>
    <nct_id>NCT03629717</nct_id>
  </id_info>
  <brief_title>RANKL Inhibition and Breast Tissue Biomarkers</brief_title>
  <official_title>RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A robust knowledge of how to reduce breast density could play a key role in breast cancer
      prevention in premenopausal women, but viable preventative targets to reduce breast
      density-associated breast cancer risk are yet to be developed. The investigators propose to
      investigate the effect of RANKL inhibition with denosumab on breast tissue markers in
      high-risk premenopausal women with dense breasts. Study findings could provide robust
      evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal
      breast cancer prevention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of denosumab on breast tissue gene RANK pathway gene expression</measure>
    <time_frame>Between baseline and day 60</time_frame>
    <description>-The investigators will evaluate changes in RANK pathway gene expression between baseline and day 60 using NanoString NCounter platform</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of denosumab on breast tissue gene expression in progesterone-regulated pathways</measure>
    <time_frame>Between baseline and day 60</time_frame>
    <description>The investigators will evaluate changes in progesterone-regulated pathways gene expression between baseline and day 60 using NanoString NCounter platform.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of denosumab on breast tissue breast tissue ki-67 proliferation</measure>
    <time_frame>Between baseline and day 60</time_frame>
    <description>The investigators will evaluate changes in ki-67 proliferation between baseline and day 60 using immunohistochemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of denosumab on breast stromal proliferation</measure>
    <time_frame>Between baseline and day 60</time_frame>
    <description>The investigators will evaluate changes in gene expression of markers of stromal proliferation between baseline and day 60 using NanoString NCounter platform.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of breast tissue RANK pathway gene expression with circulating biomarker levels</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer Prevention</condition>
  <condition>Mammographic Density</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided core needle biopsy</intervention_name>
    <description>Tissue collection for this research proposal will be used for research purposes only and will not inform participant care</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Xgeva</other_name>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>1200mg daily</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>800 IU daily</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female.

          -  Premenopausal.

          -  At least 35 years of age.

          -  Dense breasts on routine mammogram.

          -  Willing to take calcium (1,200mg) and vitamin D (800 IU) daily.

          -  At increased risk for breast cancer using any of the following:

               -  Positive family history of breast cancer

               -  Breast cancer risk prediction models

          -  Able and willing to return for repeat biopsy.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Current use of tamoxifen, aromatase inhibitors, or bisphosphonates.

          -  Concurrently participating in another cancer chemoprevention trial (unless no longer
             receiving the intervention).

          -  Pregnant or lactating.

          -  Recent tooth extraction or dental procedure.

          -  Unhealed and/or planned dental/oral surgery.

          -  History of osteonecrosis/osteomyelitis of the jaw.

          -  History of osteoporosis or severe osteopenia.

          -  Unable/unwilling to return for repeat biopsy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adetunji T Toriola, M.D., Ph.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mammographic density</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Chemoprevention</keyword>
  <keyword>Denosumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

